Trial record 33 of 2457 for: Diabetes | "Diabetes Mellitus, Insulin-Dependent"
Effects of Metreleptin in Type 1 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01268644|
Recruitment Status : Terminated (Sponsor request)
First Posted : December 31, 2010
Results First Posted : August 26, 2019
Last Update Posted : August 26, 2019
University of Texas Southwestern Medical Center
Juvenile Diabetes Research Foundation
Amylin Pharmaceuticals, LLC.
Information provided by (Responsible Party):
Abhimanyu Garg, University of Texas Southwestern Medical Center
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Type 1 Diabetes
|Recruitment Details||Patients with T1DM between the 18 and 50 years of age and with a BMI less than 27 kg/m2 and an HbA1c of 7.0–10.0% (53–86 mmol/mol) were eligible for the study.|